胸腺肽α1联合奥沙利铂和卡培他滨方案在结直肠癌术后患者辅助化疗中的应用  

The effect of Xelox combined with thymosin α1 for the treatment of postoperative colorectal cancer

作　　者：戴夕超[1] 张西志[1] 汪步海[1] 

机构地区：[1]苏北人民医院肿瘤科,江苏扬州225001

出　　处：《临床和实验医学杂志》2012年第20期1604-1606,共3页Journal of Clinical and Experimental Medicine

摘　　要：目的观察结直肠癌术后患者采用奥沙利铂和卡培他滨化疗联合胸腺肽α1的近期反应。方法将64例就诊的结直肠癌术后患者随机分为两组,实验组:采用奥沙利铂+卡培他滨(Xelox)方案联合胸腺肽α1;对照组:采用单纯奥沙利铂+卡培他滨方案化疗。观察两组治疗前后免疫指标,血常规及生活质量变化。结果实验组治疗后各项免疫指标(CD3除外)明显好于对照组(P﹤0.05),对照组免疫指标CD3、CD4、CD8、CD4/CD8化疗前后比较无明显变化,但自然杀伤细胞(NK)百分比较化疗前明显降低,两者比较差异有统计学意义。实验组治疗后白细胞计数较对照组高,两者比较差异有统计学意义。实验组治疗后KPS评分高于对照组(P<0.01)食欲、睡眠、情绪评分低于对照组(P﹤0.05)。结论结直肠癌术后患者化疗期间联合应用胸腺肽α1对于提高患者的免疫功能,改善化疗所引起的骨髓抑制和提高生活质量是有益的。Objective To investigate the short - term response of Xelox （ oxaliplatin plus capecitabine） or combined with thymosin α1 chemotherapy for colorectal cancer. Methods Sixty - four cases of colorectal cancer were randomly divided into two groups ： 32 cases in Xelox combined with thymosin α1 （ Xelox ＋ α1 ） group, 32 cases in Xelox group. The immune parameters, blood routine test and quality of life between two groups after chemotherapy were compared. Results Compared with Xelox group, immune parameters, except CD3, in Xelox ＋ α1 group were significantly improved （ P 〈 0.05 ） after chemotherapy. There were no significant changes in CD3, CD4, CD8 and CD4/CD8 in Xelox group, but the number of NK cell was significantly decreased after chemotherapy （ P 〈0.05 ）. White blood cell count in Xelox ＋ α1 group was higher than Xelox group after chemotherapy （ P 〈0.05 ）. KPS score in Xelox ＋ α1 group was higher than Xelox group （ P 〈 0.01 ） ; however, appetite, sleep, and emotional scores were lower than the control group after chemotherapy （ P 〈 0.05 ）. Conclusion The regimen of Xelox combined with thymosin α1 improves immune function and the quality of life, and decreases chemotherapy - induced bone marrow suppression in patients with colorectal cancer.

关 键 词：结直肠癌 化疗 奥沙利铂 卡培他滨 

分 类 号：R735.3[医药卫生—肿瘤]